Helus Pharma Reports First Quarter Fiscal Year 2027 Financial Results
- Appointed Michael Halstead, former President of Intra-Cellular Therapies, as Chief Executive Officer to lead Helus Pharma through late-stage development and commercialization -
- Completed enrollment in the Phase 3 APPROACH pivotal study of HLP003 in Major Depressive Disorder (“MDD”); topline data remain on track for Q4 20261,2 -
- Completed Drug-Drug Interaction (“DDI”) study demonstrated a favorable DDI profile supporting HLP003 as an adjunctive treatment for MDD -
- Continued enrollment in EMBRACE, the second pivotal study in the Phase 3 PARADIGM program -
- Continued participant rollover into EXTEND to generate long-term safety and durability data -
Helus Pharma Reports Third Quarter Fiscal Year 2026 Financial Results and Recent Business Highlights
- Cash position of US$195 million as of December 31, 2025, before adjustment for post quarter events - - Topline data readout from the Phase 2 study evaluating HLP004 in generalized anxiety disorder (“GAD”) expected in Q1 2026 -
“The third quarter reflects continued disciplined execution across Helus Pharma’s clinical and operational priorities,” said Michael Cola, Chief Executive Officer of Helus Pharma. “We are advancing a differentiated, multi-asset neuroscience portfolio with programs spanning multiple stages of development and indications. With a strong balance sheet, continued progress across our HLP003 Phase 3 and HLP004 Phase 2 programs, and a focus on scalable, repeatable clinical architectures, Helus Pharma is well positioned as we move toward upcoming clinical catalysts and long-term value creation.”
Cybin Reports Second Quarter Fiscal Year 2026 Financial Results and Recent Business Highlights
- Closed registered direct offering for aggregate gross proceeds of US$175 million (the “Registered Direct Offering”) led by a syndicate of prominent biopharmaceutical institutional investors -
- On track to report topline data from Phase 2 study evaluating CYB004 for the treatment of Generalized Anxiety Disorder (“GAD”) in Q1 20261 -
- Continues to advance Phase 3 studies of CYB003 for the adjunctive treatment of major depressive disorder (“MDD”) -
Cybin Reports Important Progress on Key Milestones and First Quarter Fiscal Year 2026 Financial Results
Cybin continues to make significant progress on its journey to bring breakthrough therapies to patients by delivering on the following key milestones
- Received European and United Kingdom Medical and Healthcare Products Regulatory Agency (“MHRA”) approval for EMBRACE, the Company’s second pivotal study evaluating CYB003 for the adjunctive treatment of Major Depressive Disorder (“MDD”) on schedule -
- EMBRACE study to enroll 330 participants at approximately 60 clinical sites across the United States, United Kingdom, Europe, and Australia1 -
